Direct Acting Antiviral Treatment for Patients with End-Stage Kidney Disease with Acute HCV Infection

BACKGROUND: Hepatitis C virus (HCV) infection is a public health problem. Such an infection is prevalent and aggressive in patients with end-stage kidney disease (ESKD). The efficacy and the safety of direct-acting antivirus (DAA) in patients with acute HCV and ESKD are under investigation. The aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussein, Nawfal R., Saleema, Zana S.M., Abd, Qais H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548205/
https://www.ncbi.nlm.nih.gov/pubmed/31205638
http://dx.doi.org/10.4084/MJHID.2019.034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548205/
https://www.ncbi.nlm.nih.gov/pubmed/31205638
http://dx.doi.org/10.4084/MJHID.2019.034

Ejemplares similares